Item Infomation
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zheng, Xie | - |
dc.contributor.author | Aaron P., Fox | - |
dc.date.accessioned | 2023-03-27T07:45:09Z | - |
dc.date.available | 2023-03-27T07:45:09Z | - |
dc.date.issued | 2023 | - |
dc.identifier.uri | https://link.springer.com/article/10.1186/s12871-023-01986-5 | - |
dc.identifier.uri | https://dlib.phenikaa-uni.edu.vn/handle/PNK/7180 | - |
dc.description | CC BY | vi |
dc.description.abstract | The α2 adrenergic receptor agonist dexmedetomidine is an important intravenous sedative with analgesic properties. Currently available dexmedetomidine reversal agents, like the α2-receptor antagonist atipamezole, cause serious adverse effects at the large dosages required for effective reversal; they are not used clinically. Without reversal agents, emergence times from dexmedetomidine sedation are slow. In this study we tested the ability of low-dose atipamezole, in combination with caffeine, to reverse dexmedetomidine sedation. The low dose of atipamezole employed should not be associated with unwanted effects. | vi |
dc.language.iso | en | vi |
dc.publisher | Springer | vi |
dc.subject | α2 adrenergic receptor agonist dexmedetomidine | vi |
dc.subject | analgesic properties | vi |
dc.title | Rapid emergence from dexmedetomidine sedation in Sprague Dawley rats by repurposing an α2-adrenergic receptor competitive antagonist in combination with caffeine | vi |
dc.type | Book | vi |
Appears in Collections | ||
OER- Y học- Điều dưỡng |
Files in This Item: